Skip to main content
Novo Nordisk logo

Novo Nordisk — Investor Relations & Filings

Ticker · NOVO ISIN · DK0062498333 LEI · 549300DAQ1CVT6CXN342 CO Manufacturing
Open in API
Filings indexed 5,600 across all filing types
Latest filing 2026-05-22 Regulatory Filings
Country DK Denmark
Listing CO NOVO

About Novo Nordisk

https://www.novonordisk.com/

Novo Nordisk is a global healthcare company dedicated to developing treatments for serious chronic diseases. With over a century of innovation, it is a world leader in diabetes care, providing a comprehensive portfolio of insulin products and GLP-1 receptor agonists. Leveraging its expertise in metabolic conditions, the company has also become a prominent force in obesity management. Novo Nordisk's therapeutic focus extends to other serious chronic conditions, including rare bleeding disorders like hemophilia and growth hormone-related disorders.

Recent filings

Filing Released Lang Actions
Novo Nordisk A/S: CHMP recommends EU approval of Wegovy® 7.2 mg in a single-dose pen, providing up to 20.7% mean weight loss (1)
Regulatory Filings Classification · 88% confidence The document is a company press release announcing a positive CHMP opinion for Wegovy® 7.2 mg in the EU and planned launch timing. It contains no financial statements, no voting results, no AGM materials, and is not a transcript or dividend notice. It is a general regulatory/compliance announcement—best fitting the Regulatory Filings (RNS) category.
2026-05-22 English
Novo Nordisk A/S: CHMP recommends EU approval of Wegovy® 7.2 mg in a single-dose pen, providing up to 20.7% mean weight loss (1)
Regulatory Filings Classification · 90% confidence The document is a company press release announcing that the EMA’s CHMP has adopted a positive opinion for marketing authorisation of a new dosage form of Wegovy. It contains no financial results, shareholder votes, management changes, or reporting of audited financial statements. It is a general regulatory announcement, making “Regulatory Filings (RNS)” the appropriate category under the fallback rule for miscellaneous regulatory updates.
2026-05-22 English
FORM 6-K
Regulatory Filings
2026-05-22 English
Novo Nordisk A/S: Wegovy® pill (oral semaglutide) recommended by CHMP for approval in the EU as the first oral GLP-1 representing the most efficacious oral obesity treatment in its class
Regulatory Filings Classification · 92% confidence The document is a company announcement disclosing material business news (CHMP positive opinion for marketing approval), formatted as a press release with inside information under Market Abuse Regulation. It does not present financial results or data, nor is it an annual/interim report, earnings release, or management call transcript. It does not solicit votes or discuss corporate governance changes. It is a regulatory announcement of material news, fitting the generic “Regulatory Filings” category (RNS).
2026-05-22 English
Novo Nordisk A/S: Wegovy® pill (oral semaglutide) recommended by CHMP for approval in the EU as the first oral GLP-1 representing the most efficacious oral obesity treatment in its class
Regulatory Filings Classification · 93% confidence The document is a corporate press release announcing a regulatory approval recommendation by the European Medicines Agency (CHMP). It does not present financial statements, earnings data, management discussion of results, or other specific report content. Instead, it is a regulatory announcement of inside information (Article 17), fitting the general “Regulatory Filings” category for miscellaneous compliance/announcement filings. Therefore, it should be classified as RNS.
2026-05-22 English
FORM SD
Regulatory Filings
2026-05-22 English

Browse filings by year

20 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.